Vir Biotechnology (VIR) Stock Forecast & Price Target

Compare

1,468 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

VIR Analyst Ratings

Strong Buy

6 Buy

0 Hold

0 Sell

Based on 6 analysts giving stock ratings to

Vir

Biotechnology

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

VIR Stock 12 Month Forecast

Average Price Target

$16.00

▲(114.19% Upside)

Based on 6 Wall Street analysts offering 12 month price targets for Vir Biotechnology in the last 3 months. The average price target is $16.00 with a high forecast of $26.00 and a low forecast of $12.00. The average price target represents a 114.19% change from the last price of $7.47.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","27":"$27","9.75":"$9.75","15.5":"$15.5","21.25":"$21.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$26.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$16.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,9.75,15.5,21.25,27],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.71,9.116923076923078,10.523846153846154,11.930769230769231,13.337692307692308,14.744615384615384,16.15153846153846,17.55846153846154,18.965384615384615,20.372307692307693,21.779230769230768,23.186153846153847,24.593076923076925,{"y":26,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.71,8.347692307692308,8.985384615384616,9.623076923076923,10.260769230769231,10.898461538461538,11.536153846153846,12.173846153846153,12.811538461538461,13.44923076923077,14.086923076923076,14.724615384615383,15.362307692307692,{"y":16,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.71,8.04,8.37,8.7,9.03,9.36,9.69,10.02,10.35,10.68,11.01,11.34,11.67,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":10.4,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.39,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.08,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.07,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.11,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.03,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.7,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.96,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 43, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.07,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 51, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.03,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 77, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.71,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 54, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$26.00

Average Price Target$16.00

Lowest Price Target$12.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Etzer Darout

Barclays

$24→$26

Buy

248.06%

Upside

Reiterated

02/17/26

Barclays Remains a Buy on Vir Biotechnology (VIR)

Alec Stranahan

Bank of America Securities

$13

Buy

74.03%

Upside

Reiterated

02/11/26

Vir Biotechnology: Undervalued T‑Cell Engager Platform with Differentiated Safety Profile and Upside from VIR-5500 in mCRPC

Joseph Stringer

Needham

$14

Buy

87.42%

Upside

Reiterated

02/09/26

Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (NASDAQ: VIR), M3 (Other OTC: MTHRF) and Sarepta Therapeutics (NASDAQ: SRPT)

Patrick Trucchio

H.C. Wainwright

$15

Buy

100.80%

Upside

Reiterated

01/21/26

Analysts Are Bullish on Top Healthcare Stocks: Aprea Therapeutics (APRE), Arcellx Inc (ACLX)

Phil Nadeau

TD Cowen

Buy

―

Reiterated

01/13/26

TD Cowen Sticks to Its Buy Rating for Vir Biotechnology (VIR)

Unknown Analyst

Raymond James

Not Ranked

Raymond James

$5.72→$12

Buy

60.64%

Upside

Reiterated

01/13/26

Raymond James Sticks to Their Buy Rating for Vir Biotechnology (VIR)

Michael Ulz

Morgan Stanley

$20

Buy

167.74%

Upside

Reiterated

11/10/25

Morgan Stanley Sticks to Its Buy Rating for Vir Biotechnology (VIR)

Cory Kasimov

Evercore ISI

$12

Buy

60.64%

Upside

Reiterated

11/06/25

Evercore ISI Remains a Buy on Vir Biotechnology (VIR)

Roanna Ruiz

Leerink Partners

$16

Buy

114.19%

Upside

Reiterated

08/06/25

Vir Biotechnology: Strong Execution and Promising Prospects Justify Buy Rating

Eric Joseph

J.P. Morgan

$14

Hold

87.42%

Upside

Reiterated

05/07/25

Analysts Offer Insights on Healthcare Companies: aTyr Pharma (NASDAQ: ATYR), Vir Biotechnology (NASDAQ: VIR) and Astellas Pharma (Other OTC: ALPMF)

Paul Choi

Goldman Sachs

$28→$21

Buy

181.12%

Upside

Reiterated

04/16/25

Vir Biotechnology (VIR) PT Lowered to $21 at Goldman SachsGoldman Sachs analyst Paul Choi lowered the price target on Vir Biotechnology (NASDAQ: VIR) to $21.00 (from $28.00) while maintaining a Buy rating.

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Etzer Darout

Barclays

$24→$26

Buy

248.06%

Upside

Reiterated

02/17/26

Barclays Remains a Buy on Vir Biotechnology (VIR)

Alec Stranahan

Bank of America Securities

$13

Buy

74.03%

Upside

Reiterated

02/11/26

Vir Biotechnology: Undervalued T‑Cell Engager Platform with Differentiated Safety Profile and Upside from VIR-5500 in mCRPC

Joseph Stringer

Needham

$14

Buy

87.42%

Upside

Reiterated

02/09/26

Analysts Offer Insights on Healthcare Companies: Vir Biotechnology (NASDAQ: VIR), M3 (Other OTC: MTHRF) and Sarepta Therapeutics (NASDAQ: SRPT)

Patrick Trucchio

H.C. Wainwright

$15

Buy

100.80%

Upside

Reiterated

01/21/26

Analysts Are Bullish on Top Healthcare Stocks: Aprea Therapeutics (APRE), Arcellx Inc (ACLX)

Phil Nadeau

TD Cowen

Buy

―

Reiterated

01/13/26

TD Cowen Sticks to Its Buy Rating for Vir Biotechnology (VIR)

Unknown Analyst

Raymond James

Not Ranked

Raymond James

$5.72→$12

Buy

60.64%

Upside

Reiterated

01/13/26

Raymond James Sticks to Their Buy Rating for Vir Biotechnology (VIR)

Michael Ulz

Morgan Stanley

$20

Buy

167.74%

Upside

Reiterated

11/10/25

Morgan Stanley Sticks to Its Buy Rating for Vir Biotechnology (VIR)

Cory Kasimov

Evercore ISI

$12

Buy

60.64%

Upside

Reiterated

11/06/25

Evercore ISI Remains a Buy on Vir Biotechnology (VIR)

Roanna Ruiz

Leerink Partners

$16

Buy

114.19%

Upside

Reiterated

08/06/25

Vir Biotechnology: Strong Execution and Promising Prospects Justify Buy Rating

Eric Joseph

J.P. Morgan

$14

Hold

87.42%

Upside

Reiterated

05/07/25

Analysts Offer Insights on Healthcare Companies: aTyr Pharma (NASDAQ: ATYR), Vir Biotechnology (NASDAQ: VIR) and Astellas Pharma (Other OTC: ALPMF)

Paul Choi

Goldman Sachs

$28→$21

Buy

181.12%

Upside

Reiterated

04/16/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Vir Biotechnology

3 Months

xxx

Success Rate

9/15 ratings generated profit

Average Return

+5.17%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +5.17% per trade.

1 Year

Phil NadeauTD Cowen

Success Rate

9/15 ratings generated profit

Average Return

+24.37%

reiterated a buy rating last month

Copying Phil Nadeau's trades and holding each position for 1 Year would result in 60.00% of your transactions generating a profit, with an average return of +24.37% per trade.

2 Years

xxx

Success Rate

7/15 ratings generated profit

Average Return

+7.73%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 46.67% of your transactions generating a profit, with an average return of +7.73% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

VIR Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

101

In the current month, VIR has received 16 Buy Ratings, 54 Hold Ratings, and 0 Sell Ratings. VIR average Analyst price target in the past 3 months is 16.00.

Each month's total comprises the sum of three months' worth of ratings.

VIR Financial Forecast

VIR Earnings Forecast

Next quarter’s earnings estimate for VIR is -$0.49 with a range of -$0.80 to -$0.13. The previous quarter’s EPS was -$1.17. VIR beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year VIR has Performed in-line its overall industry.

VIR Sales Forecast

Next quarter’s sales forecast for VIR is $19.91M with a range of $240.00K to $66.00M. The previous quarter’s sales results were $240.00K. VIR beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year VIR has Performed in-line its overall industry.

VIR Stock Forecast FAQ

What is VIR’s average 12-month price target, according to analysts?

Based on analyst ratings, Vir Biotechnology’s 12-month average price target is 16.00.

What is VIR’s upside potential, based on the analysts’ average price target?

Vir Biotechnology has 114.19% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is VIR a Buy, Sell or Hold?

Vir Biotechnology has a consensus rating of Strong Buy which is based on 6 buy ratings, 0 hold ratings and 0 sell ratings.

What is Vir Biotechnology’s price target?

The average price target for Vir Biotechnology is 16.00. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $26.00 ,the lowest forecast is $12.00. The average price target represents 114.19% Increase from the current price of $7.47.

What do analysts say about Vir Biotechnology?

Vir Biotechnology’s analyst rating consensus is a Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.

How can I buy shares of VIR?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Vir Biotechnology (VIR) Stock Forecast & Price Target

VIR Analyst Ratings

VIR Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Vir Biotechnology

VIR Analyst Recommendation Trends

VIR Financial Forecast

VIR Earnings Forecast

VIR Sales Forecast

VIR Stock Forecast FAQ

Detailed List of Analyst Forecasts